Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis

NCT01674309 is registered in ClinicalTrials.gov with Federation Francophone de Cancerologie Digestive as lead sponsor.

NCT NCT01674309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01674309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis
Lead sponsor
Federation Francophone de Cancerologie Digestive
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2012
Completion date
October 31, 2016
Enrollment
65 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of rectum